1. The metabolic and hormonal responses to intravenous glucose (0.5 g/kg body wt.) were studied in ten normal subjects and thirteen patients with active chronic hepatitis. Untreated patients showed a decreased initial insulin response and glucose intolerance (KG, 0.89 fO-lO%/min compared with 2*34+0*24%/min), together with a paradoxical rise in growth hormone.
may be evidence of high circulating insulin concentrations with peripheral insulin resistance (Megyesi et al., 1967; Samols & Holdsworth, 1968) or low-to-normal insulin amounts with glucose intolerance (Samols & Holdsworth, 1968 ; Hernandez et al., 1969) . Abnormalities of glucose and insulin metabolism have also been noted in acute viral hepatitis (Hernandez el al., 1969) and obstructive hepatic disease (Berkowitz, Blinkoff & Glassman, 1966) .
Increases in serum growth hormone (Samaan et al., 1969; Becker, Cook & Wright, 1969; Conn & Daughaday, 1970) , plasma non-esterified fatty acids (Mortiaux & Dawson, 1961) , 2-oxoglutarate (Dawson, De Groote, Rosenthal & Sherlock, 1957) , pyruvate (Amatuzio & Nesbitt, 1950) and lactate (Tranquada, 1964) have been reported in a large variety of diseases of the liver. However, little attempt has been made to correlate these various changes with each other or with the type and extent of the disease.
There have been few studies of metabolic abnormalities in active chronic hepatitis other than that by Becker et ctl. (1 969) . We report here the results of intravenous glucose tolerance tests in which growth hormone, insulin and a wide variety of metabolites were estimated. The aim was to characterize the metabolic changes in active chronic hepatitis and in the long term to establish whether such changes were specific to the disease and could be correlated with its activity or extent.
P A T I E N T S A N D M E T H O D S
The diagnosis of active chronic hepatitis was based on the criteria of Mistilis (1969) and Sherlock (1968) . The following clinical, biochemical, histological and immunological features were present in all patients at some time during the course of their illness:
(a) Symptoms or signs of chronic liver disease for more than 6 months in the absence of a history of high alcohol intake or exposure to other hepatotoxins.
(b) Elevation of the aspartate aminotransferase, serum globulin and serum bilirubin concentrations.
(c) Histological features of chronic aggressive hepatitis on biopsy (De Groote, Desmet, Gedigk, Korb, Popper, Poulson, Scheuer, Schmid, Thaler, Uehlinger & Wepler, 1968) .
(d) Antibody to smooth muscle, antinuclear factor or antibodies to mitochondriain theserum. Clinical details, including liver function tests and antibody studies at the time of testing, are shown in Table 1 . Two patients (cases 12 and 13) had biopsy evidence of severe cirrhosis. All other patients had either no evidence of or only mild cirrhotic changes. All were female. The average duration of the disease at the time of testing was 2.6 years; the range was from 2 months to 8.5 years. Mean body weight was 107 f 7% (k SEM) of ideal (Metropolitan Life Insurance Tables) in the untreated patients without pronounced cirrhosis and 101 +8% in steroid-treated patients. A group of ten normal females, age range 20-56 years, were used for comparison. None had clinical or biochemical evidence of liver disease or diabetes mellitus. Their weights were 1 15 f 6% of ideal body weight. None was receiving any form of medication or oral contraceptive steroids. Consent from all patients and normal subjects was obtained before testing. 5 Diabetic father.
7 Normal values. in the month before testing. Subjects were fasted from 10 p.m. on the previous evening and remained recumbent for at least 30 min before the test. All normal subjects were out-patients at the time of testing whereas five of the eight 'non-cirrhotic' patients and two of the five steroid-treated patients were in-patients. Subjects 7 and 8 were in-patients and subject 6 was an out-patient at the time of their second test. Subjects tested as out-patients remained recumbent for 30-60 min before testing. All blood samples were drawn from an indwelling needle in the antecubital vein with no venous occlusion, the line being kept patent with a slow saline infusion. Two samples of blood were drawn from fasting patients at an interval of 10 min for hormones and metabolites and then 50% (w/v) glucose (0-5 g/kg body wt.) was infused into the contralateral arm in 1 to 2 min. Blood samples were drawn at 1, 3, 5, 10, 20, 30 , 40, 50 and 60 min for measurement of serum insulin, growth hormone and glucose, and at 30,40 and 60 min for other metabolites. Immediately after it was withdrawn, 5 ml of blood was added to 5 ml of ice-cold 10% perchloric acid for metabolite assays, 5 ml was added to a cold heparinized tube for free fatty acid and triglyceride assays, 2 ml was added to a fluoride tube for blood glucose determination and 4 ml was added to a plain tube for serum insulin and growth hormone measurement. (Hohorst, Kreutz & Bucher, 1959) , 2-oxoglutarate (Bergmeyer & Bernt, 1963b) , glutamate (Bernt & Bergmeyer, 1963) , glutamine (Lund, 1970) (Kreutz, 1962) and plasma triglycerides (Eggstein & Kreutz, 1966) . Plasma free fatty acids were measured colorimetrically (Itaya & Ui, 1965) . Liver function tests were performed in the routine clinical chemistry laboratory; antinuclear factor (ANF), antibodies to smooth muscle and mitochondria, and Australia antigen were measured by indirect immunofluorescence as described by Perrett, Higgins, Johnston, Massarella, Truelove & Wright (1971) .
Special chemicals. Anti-insulin serum was a gift from Dr P. H. Wright. The '251-labelled insulin was obtained from Abbott Laboratories, Chicago, Ill., U.S.A., and human insulin standard was a gift from the Medical Research Council, Biological Standards Division, Mill Hill, London, N.W.7, U.K.
Statistical methods. The P values refer to the Student's t test.
R E S U L T S

Liver function tests and autoantibodies
Liver function tests and antibody results at the time of testing are shown in Table 1 . The state of activity of the hepatitis as judged by liver function tests varied. All patients had one or more autoantibodies in their serum; none had Australia antigen.
Blood glucose and serum insulin
Controls and untreated patients. Fig. 1 shows the blood glucose and serum insulin values in response to intravenous glucose infusion in normal subjects and eight patients with untreated active chronic hepatitis. The fasting glucose values of the patients (76 f 3 mg/lOO ml) were significantly higher than those found in normal subjects (66+3 mg/100 ml), although fasting serum insulin values were not different (Table 2) disappearance rate (Kc) was considerably slower in the active chronic hepatitis patients. The respective disappearance rates were 2-34+0.22%/min and 0.89 +0*10%lmin (P<O.Ol). Thus there was marked and significant glucose intolerance in patients with active chronic hepatitis.
The response of serum insulin to intravenous glucose also differed between the two groups. The initial peak in serum insulin was smaller in the patients than in normals. However, in the later stages of the test the serum insulin showed a secondary rise and by the end of the test was significantly higher in the patients than in normah. The early response is shown in Fig. 2 where the area under the insulin curve in the first 5 rnin is plotted as a histogram. The value is obtained from the A insulin values at 1, 3 and 5 min. There is a markedly decreased initial release of insulin in six of the eight active chronic hepatitis patients. The two patients (cases 12 and 13) who showed severe cirrhosis on biopsy and who differed clinically, histologically and biochemically from the other eight untreated patients and patients 9, 10 and 11 are not included in Figs. 1 and 2 . Values in blood of fasting patients are shown in Table 2 . Insulin amounts were raised at 15.5 and 13-6 pi.u./ml in cases 12 and I 3 and peak responses were 238 pi.u./ml and 72 pi.u./ml respectively. Serum insulin was still 75 pi.u./ml and 71 pi.u./ml at 60 min in the two patients, much higher than in the noncirrhotic subjects. Despite the high circulating insulin amounts glucose tolerance was borderline (&, 1*13%/rnin) in case 12 and severely impaired in case 13 (&, Glucocorticoid-treated patients. In five patients tested after or while receiving steroid treatment a different pattern was seen. Fasting glucose was 69+6 mg/100 ml, no different from controls, whereas fasting serum insulin 10.4+2.1 pi.u./ml was higher than in controls and tended to be higher than in untreated patients ( Table 2) . The most notable finding was a marked improvement in glucose tolerance. The mean glucose disappearance rate was 1.42 k O*12%/min with the lowest value being l-l8%/min. The two patients tested both before and after steroid therapy each showed improved KG values. Insulin secretion was increased with steroid treatment, particularly in the later stages of the test. Thus in four patients the 60 min serum insulin value was 57 f 20 pi.u./ml compared with 15 + 3 pi.u./ml in normal subjects and 31 & 5 pi.u./ml in untreated patients. These findings are contrary to those observed in normal subjects and mild diabetics where exogenous steroids caused hyperinsulinism but decreased glucose tolerance (Perley & Kipnis, 1966) .
Serum growth hormone
Fasting serum growth hormone values for the eight untreated patients (without cirrhosis)
did not differ significantly from control subjects (3.6 k 0.8 ng/ml compared with 6-9 + 2-3 ng/ml) ( Table 3) . However, in eight of ten tests done on untreated patients values 60 min after glucose, although variable, were significantly higher than both fasting values and the 60 min control group values. Such a paradoxical rise was not seen in any of the ten normal subjects, suppression being found in all cases. Steroid treatment had little effect on fasting growth hormone values or their paradoxical rise although the two patients tested both before and after treatment had lower values throughout their repeat tests. In contrast, case 12, with severe cirrhosis, had elevated fasting values and these persisted throughout.
Blood lactate and pyruvate
There was no difference in fasting blood lactate and pyruvate values between control and disease groups (Table 2) . After intravenous glucose the normal response was a mean increase of 0.42 mmol/l for lactate and 0.026 mmol/l for pyruvate, with the peak rise occurring at either 30 or 40 rnin (Fig. 3) . The eight patients with active chronic hepatitis and without cirrhosis showed a significantly slower rise in both metabolites, the peak values occurring at production (mainly muscle) and hepatic removal. However, there was reasonable correlation between the time at which the peak lactate value occurred and the glucose disappearance rate. Thus it can be concluded that the delayed rise in blood lactate and pyruvate is probably a consequence of the impaired glucose utilization and not of accelerated hepatic removal. This correlation is even stronger if the 30 min rise in lactate is plotted against initial secretion (Fig. 4) . In normal subjects there was a direct relation between initial insulin secretion and
. . -- lactate rise (r = 0.85) whereas a similar but different straight line describes the relationship in patients with untreated active chronic hepatitis (r = 0.90). The shift of the line to the left implies a degree of peripheral insulin resistance as well as a diminished circulating insulin concentration.
The steroid-treated patients showed a different response. Three of the five had an excessive rise in lactate, the mean rise at 30 min being 0-54 mmol/ 1. When these values were compared with initial insulin secretion the line was shifted to the right compared with normal. This response is similar to that seen in patients with cirrhosis (K. G. M. M. Alberti, D. H. Williamson & R. Wright, unpublished work). It is possible that the improved glucose utilization after steroid therapy unmasks decreased ability of the liver to dispose of lactate. Alternatively it could be directly attributed to steroid therapy.
The two patients with severe cirrhosis (cases 12 and 13) had elevated fasting blood lactate values (1.47 and 1.53 mmol/l) and elevated pyruvate (0.108 and 0.117 mmol/l). The rise in lactate after glucose was retarded and correlated well with glucose tolerance, but not with insulin secretion. 
Blood 2-oxoglutarate
There was no difference between the active chronic hepatitis group (0.01 3 +0.001 mmol/l) and the control group (0.01 1 fO.001 mmol/l). The two cirrhotic patients had elevated values (0.017 and 0.023 mmol/l). The two groups reached peaks of 0-018fO.003 mmol/l and 0.014f 0.001 mmol/l at 40 min and 60 min after glucose respectively. The difference at 40 min was significant (P<0.05). Treatment with steroids had no effect.
Blood glutamate and blood glutamine
Mean fasting glutamate was 0.1 55 f0-012 mmol/l in the active chronic hepatitis patients and 0.139 f0.007 mmol/l in the control subjects. Blood glutamine values were 0.686 f0.042
mmol/l and 0.637 f0.023 mmol/l in the hepatitis patients and the normal subjects respectively.
Blood 3-hydroxybutyrate and acetoacetate
Fasting blood 3-hydroxybutyrate and acetoacetate values were raised in the active chronic hepatitis patients (Table 2) . However, after glucose infusion they decreased markedly and were the same as in the control group by the end of the test (Fig. 5) . In the steroid group three of the five patients had normal fasting values while both cirrhotic patients had values significantly lower than in the non-cirrhotic group (Table 2) . 
Non-esterijied fatty acids, glycerol and triglycerides
Fasting free fatty acid and glycerol values were elevated in the untreated chronic hepatitis group compared to control subjects (Table 2) but were similar by the end of the test. Fasting plasma triglycerides were raised in the hepatitis patients and decreased less after glucose than in normal subjects (P<0.02). Three of four treated subjects had normal free fatty acids and triglyceride values but they still had raised fasting blood glycerol values. Similarly the severely cirrhotic patients had normal fasting blood free fatty acids and triglycerides with markedly elevated blood glycerol concentrations ( Table 2) .
Sequential tests
Cases 6, 7 and 8 had two intravenous glucose tolerance tests without intervening steroid treatment. No consistent changes occurred. The blood ketone body concentrations, glucose tolerance and rise in blood lactate remained abnormal.
D I S C U S S I O N
In the present study untreated patients with active chronic hepatitis in the absence of severe cirrhosis showed a diminished early insulin secretion in response to glucose with a secondary rise in the later stages of the test. The type of response seen in untreated active chronic hepatitis was typical of mild diabetes and could have been due to decreased secretion of insulin or its increased hepatic clearance. Corticosteroid-treated patients and patients with active chronic hepatitis with severe cirrhosis showed different patterns. Raised insulin concentrations have been reported in cirrhosis (Megyesi et al., 1967; Samols & Holdsworth, 1968; Samaan et al., 1969; Creutzfeldt, Frerichs & Sickinger, 1970) . This has been ascribed to portal-systemic shunting or peripheral insulin resistance (Samols & Holdsworth, 1968) . Such resistance was present to a slight extent in our untreated mild patients and was pronounced in the corticosteroid-treated and cirrhotic groups.
The other changes in the untreated group were probably secondary to the decreased circulating insulin concentration. Thus glucose intolerance, raised fasting blood free fatty acids, glycerol, triglyceride and ketone body concentrations would result from the hypoinsulinism. In addition, the decreased rate of rise of blood lactate and pyruvate after glucose has been described in maturity-onset diabetes mellitus (Doar, Cramp, Maw, Seed & Wynn, 1970) and is directly related to the decreased initial insulin secretion (Fig. 4) .
The reasons for the similarity of the response to intravenous glucose of patients with untreated active chronic hepatitis to those with borderline diabetes mellitus is unclear. Active chronic hepatitis is a systemic disorder with widespread tissue involvement including a variety of endocrine disorders (Sherlock, 1968; Mistilis, 1969) . Such disorders might be mediated by an abnormal immune response but although a wide variety of autoantibodies have been described in active chronic hepatitis we know of no reports of antibodies to the pancreatic P-cell and circulating anti-insulin antibodies could not be detected in any of patients when their serum was titrated against 125T-labelled insulin in the absence of added antibody (K. G. M. M. Alberti, unpublished work). It is possible, although improbable, that seven of our eight patients with decreased insulin secretion had early classical diabetes mellitus. However, in contrast with the diabetes seen in our patients, those with classical diabetes mellitus show deterioration in glucose tolerance with steroid treatment (Williams, 1968) . This suggests that the aetiology of the diabetes seen in the two situations might differ.
It has been reported that obesity results in early and sustained hyperinsulinism after intravenous glucose (Karam, Grodsky & Forsham, 1963) . This is often associated with glucose intolerance. Our normal subjects were slightly heavier than the untreated active chronic hepatitis patients (115% compared with 107% of ideal body weight) although the difference was not significant. Simms, Kelleher, Horton, Gluck, Goldman & Rowe (1969) showed that in experimental obesity a difference of 10-20% was associated with a rise in fasting insulin but an insignificant rise in early insulin secretion. On the other hand, Soeldner, Sonksen & Gleason (1970) in the 5 h oral glucose tolerance test showed a significant increase in insulin response in the heavier group when comparing normal subjects with body weight less than 100% of ideal and those with body weights above 100% ideal. However, the groups with 101-l05%, 106-1 10% and 11 1-1 15% ideal body weight showed no significant differences. Therefore it is felt that the small changes present in our subjects could not account for the differences between the hepatitis and normal groups. Again it is possible that some difference may have been caused by the fact that all the normal subjects, but only three of eight active chronic hepatitis patients, were out-patients at the time of testing. Again the differences between the two groups are large and unlikely to result from this alone.
Our insulin results are at variance with those reported by Becker et al. (1969) who found impaired oral and intravenous glucose tolerance and paradoxical elevation of growth hormone in three groups of patients with active chronic hepatitis described as early, moderate or advanced. These authors found hyperinsulinism in all groups during both oral and intravenous tests. However, half of their patients were receiving corticosteroids at the time of testing and although untreated patients showed significant hyperinsulinism at 0, 90 and 180 min during oral testing, only in the advanced cirrhotic group was significant hyperinsulinism present on intravenous testing. The paradoxical rise in growth hormone seen in our patients is in agreement with the findings of these authors as is the failure of steroid therapy to rectify this. Most patients showed growth hormone responses similar to those found in their 'early' group.
Our findings suggest that active chronic hepatitis that is uncomplicated by severe cirrhosis is characterized by changes in carbohydrate and lipid metabolism that can be explained by low circulating insulin concentrations. Treatment with corticosteroids reverses many of the changes but also results in hyperinsulinism and an increased blood lactate response to glucose. Severe cirrhosis appears to change the biochemical pattern of the disease; the two patients in the group behaved like other cirrhotics. Further serial studies both with and without treatment during progression to cirrhosis may be of great value in defining the natural history of the disease in biochemical terms.
